Stephen Beaupre, MD
Internal Medicine · Cranston, RINPI 1619994217
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 431 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 431 payments — averaging $17.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Pfizer$1K
- Johnson & Johnson$421
- AbbVie$420
- Amgen$367
- plus $2K from 30 others
What the payments were for
- Food & beverage$7,577100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 94 | $1,707 |
| GSK | 74 | $1,311 |
| Pfizer | 95 | $1,251 |
| Johnson & Johnson | 23 | $421 |
| AbbVie | 21 | $420 |
| Amgen | 18 | $367 |
| Boehringer Ingelheim | 15 | $328 |
| Amarin Pharma, Inc. | 15 | $271 |
| Exact Sciences | 11 | $216 |
| Nestle Healthcare Nutrition Inc. | 7 | $141 |
| Genentech USA, Inc. | 6 | $126 |
| Lilly USA, LLC | 6 | $116 |
| Esperion Therapeutics, Inc. | 6 | $115 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $83 |
| Harmony Biosciences LLC | 1 | $81 |
| Novo Nordisk | 3 | $62 |
| Abbott | 2 | $51 |
| Sumitomo Pharma America, Inc. | 2 | $50 |
| Sunovion Pharmaceuticals Inc. | 3 | $43 |
| Melinta Therapeutics, LLC | 2 | $42 |
| Regeneron Healthcare Solutions, Inc. | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Boston Scientific | 1 | $33 |
| Novartis | 2 | $33 |
| Merck | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
| Actelion Pharmaceuticals US, Inc. | 1 | $26 |
| Shire North American Group Inc | 1 | $23 |
| Eisai Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| Gilead | 1 | $15 |
| Mylan Specialty L.p. | 1 | $12 |
| Biodelivery Sciences International, Inc. | 1 | $12 |
How this compares
$7,590 in reported general payments places this provider in the 95th percentile of 808 internal medicine providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 82 | $95,383 |
| JanuviaSitagliptin Phosphate | 52 | $63,934 |
| EliquisApixaban | 69 | $53,708 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $37,479 |
| FarxigaDapagliflozin Propanediol | 13 | $21,229 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 62 | $20,350 |
| XareltoRivaroxaban | 24 | $18,602 |
| MounjaroTirzepatide | 11 | $11,976 |
| JardianceEmpagliflozin | 16 | $11,473 |
| TrulicityDulaglutide | 11 | $10,814 |
| Omeprazole | 545 | $10,443 |
| SymbicortBudesonide/Formoterol Fumarate | 39 | $10,104 |
| Atorvastatin Calcium | 625 | $8,312 |
| Spiriva HandihalerTiotropium Bromide | 12 | $8,042 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $6,641 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $62 | $95,38382 claims |
| PfizerEliquis, Abrysvo | $1,251 | $74,057131 claims |
| MerckJanuvia | $31 | $63,93452 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $1,311 | $41,52663 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $1,707 | $37,97463 claims |
| Lilly USA, LLCMounjaro, Trulicity | $116 | $22,79022 claims |
| Johnson & JohnsonXarelto | $421 | $18,60224 claims |
| Boehringer IngelheimJardiance | $328 | $11,47316 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $16 | $5,413474 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 808 internal medicine providers in Rhode Island.
Other internal medicine in Cranston
- Gregory AllenCranston$38K
- Joseph CampbellCranston$13K
- Dennis BotelhoCranston$12K
- Usha PanneerselvamCranston$7K
- Olga TverskayaCranston$6K
- Leah AdamsCranston$4K
- William BeliveauJohnson$951K
- Katarzyna Gilek-SeibertProvidence$131K
- Randall InghamProvidence$100K
- Frank D'alessandroLincoln$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.